SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:985b8c19-52b9-40c8-b59d-753aec535012"
 

Search: onr:"swepub:oai:lup.lub.lu.se:985b8c19-52b9-40c8-b59d-753aec535012" > Precision Prognosti...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Ahmad, AbrarLund University,Lunds universitet,Diabetiska komplikationer,Forskargrupper vid Lunds universitet,Diabetic Complications,Lund University Research Groups (author)

Precision Prognostics for Cardiovascular Disease in Type 2 Diabetes : A Systematic Review and Meta-analysis

  • BookEnglish2023

Publisher, publication year, extent ...

  • 2023

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:985b8c19-52b9-40c8-b59d-753aec535012
  • https://lup.lub.lu.se/record/985b8c19-52b9-40c8-b59d-753aec535012URI
  • https://doi.org/10.1101/2023.04.26.23289177DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ovr swepub-publicationtype
  • Subject category:vet swepub-contenttype

Notes

  • BACKGROUND: Precision medicine has the potential to improve cardiovascular disease (CVD) risk prediction in individuals with type 2 diabetes (T2D).METHODS: We conducted a systematic review and meta-analysis of longitudinal studies to identify potentially novel prognostic factors that could improve CVD risk prediction in T2D. Out of 9380 studies identified, 416 studies met inclusion criteria. Outcomes were reported for 321 biomarker studies, 48 genetic marker studies, and 47 risk score/model studies.Out of all evaluated biomarkers, only 13 showed improvement in prediction performance. Results of pooled meta-analyses, non-pooled analyses, and assessments of improvement in prediction performance and risk of bias, yielded the highest predictive utility for N-terminal pro b-type natriuretic peptide (NT-proBNP) (high-evidence), troponin-T (TnT) (moderate-evidence), triglyceride-glucose (TyG) index (moderate-evidence), Genetic Risk Score for Coronary Heart Disease (GRS-CHD) (moderate-evidence); moderate predictive utility for coronary computed tomography angiography (low-evidence), single-photon emission computed tomography (low-evidence), pulse wave velocity (moderate-evidence); and low predictive utility for C-reactive protein (moderate-evidence), coronary artery calcium score (low-evidence), galectin-3 (low-evidence), troponin-I (low-evidence), carotid plaque (low-evidence), and growth differentiation factor-15 (low-evidence). Risk scores showed modest discrimination on internal validation, with lower performance on external validation.CONCLUSIONS: Despite high interest in this topic, very few studies conducted rigorous analyses to demonstrate incremental predictive utility beyond established CVD risk factors for T2D. The most promising markers identified were NT-proBNP, TnT, TyG and GRS-CHD, with the highest strength of evidence for NT-proBNP. Further research is needed to determine their clinical utility in risk stratification and management of CVD in T2D.PLAIN LANGUAGE SUMMARY: Patients with T2D are at high risk for CVD but predicting who will experience a cardiac event is challenging. Current risk tools and prognostic factors, such as laboratory tests, may not accurately predict risk in different patient populations. There is a need for personalized risk prediction tools to identify patients more accurately so that CVD prevention can be targeted to those who need it most. This study examined novel biomarkers, genetic markers, and risk scores on the prediction of CVD in individuals with T2D. We found that four laboratory markers and a genetic risk score for CHD had high predictive utility beyond traditional CVD risk factors and that risk scores had modest predictive utility when tested in diverse populations, but more studies are needed to determine their usefulness in clinical practice. The highest strength of evidence was observed for NT-proBNP, a laboratory test currently used to monitor patients with heart failure but not currently used in clinical practice for the purpose of CVD prediction in T2D.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Lim, Lee-LingUniversity of Malaya (author)
  • Morieri, Mario LucaUniversity of Padova (author)
  • Tam, Claudia Ha-TingChinese University of Hong Kong (author)
  • Cheng, FeifeiChongqing University (author)
  • Chikowore, TinasheUniversity of the Witwatersrand (author)
  • Dudenhöffer-Pfeifer, MonikaLund University,Lunds universitet,Diabetiska komplikationer,Forskargrupper vid Lunds universitet,Diabetic Complications,Lund University Research Groups(Swepub:lu)med-md- (author)
  • Fitipaldi, HugoLund University,Lunds universitet,Genetisk och molekylär epidemiologi,Forskargrupper vid Lunds universitet,Genetic and Molecular Epidemiology,Lund University Research Groups(Swepub:lu)hu3745fi (author)
  • Huang, ChuiguoChinese University of Hong Kong (author)
  • Kanbour, SarahAMAN Hospital (author)
  • Sarkar, SudipaJohns Hopkins University (author)
  • Koivula, Robert WilhelmUniversity of Oxford(Swepub:lu)med-rkl (author)
  • Motala, Ayesha AUniversity of KwaZulu-Natal (author)
  • Tye, Sok CinUniversity Medical Center Groningen (author)
  • Yu, Gechang (author)
  • Zhang, Yingchai (author)
  • Provenzano, Michele (author)
  • Sherifali, Diana (author)
  • de Souza, Russel (author)
  • Tobias, Deirdre Kay (author)
  • Gomez, Maria FLund University,Lunds universitet,Diabetiska komplikationer,Forskargrupper vid Lunds universitet,Diabetic Complications,Lund University Research Groups,Aarhus University(Swepub:lu)mphy-mgo (author)
  • Ma, Ronald C W (author)
  • Mathioudakis, Nestoras (author)
  • Diabetiska komplikationerForskargrupper vid Lunds universitet (creator_code:org_t)

Internet link

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view